| Liu, Zhijun |
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 500 | RoW | TQH2722 injection, Placebo of TQH2722 injection | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Atopic Dermatitis | 10/25 | 06/26 | | |
| Zhang, Yuanyuan |
PDO, NCT06077591: Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids () Guided Therapy in Patients with Advanced/ Inoperable Solid Tumors |
|
|
| Recruiting | 3 | 40 | RoW | Patient-Derived Tumor Organoids | Chinese University of Hong Kong | Hepatocellular Carcinoma, Colorectal Cancer | 02/27 | 02/28 | | |
NCT04003246: Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 50 | US | Thoracic RT and Durvalumab, Consolidative Durvalumab | University of Texas Southwestern Medical Center, AstraZeneca | Non Small Cell Lung Cancer, Lung Cancer Stage III | 08/25 | 08/26 | | |
WEE1, NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 350 | US, RoW | IMP7068 | Impact Therapeutics, Inc., Covance | Advanced Solid Tumors | 04/23 | 08/23 | | |
